Bicycle Therapeutics (BCYC)
(Delayed Data from NSDQ)
$25.41 USD
-0.09 (-0.35%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $25.39 -0.02 (-0.08%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
BCYC 25.41 -0.09(-0.35%)
Will BCYC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BCYC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BCYC
What Makes Bicycle Therapeutics (BCYC) a New Buy Stock
Wall Street Analysts See an 88.94% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High?
BCYC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Bicycle Therapeutics (BCYC) This Year?
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
Is Bicycle Therapeutics (BCYC) Stock Outpacing Its Medical Peers This Year?
Other News for BCYC
Oppenheimer Keeps Their Buy Rating on Bicycle Therapeutics (BCYC)
Bicycle Therapeutics (BCYC) Receives a Buy from TD Cowen
3 Best Stocks to Buy Now, 9/16/2024, According to Top AnalystsÂ
Bicycle Therapeutics: A Strong Buy on Robust Clinical Data and Market Potential for mUC Treatments
Buy Rating Justified by Promising Clinical Data from Bicycle Therapeutics’ Drug Pipeline